A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
Overview
- Phase
- Phase 2
- Intervention
- AK112 Injection
- Conditions
- NSCLC
- Sponsor
- Sun Yat-sen University
- Enrollment
- 55
- Locations
- 1
- Primary Endpoint
- iPFS
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
A multicenter, single-arm, open-label study evaluating the safety and efficacy of AK112 combined with chemotherapy as first-line treatment for non-squamous NSCLC patients with BRAIN metastases and negative driver genes
Detailed Description
This is a multicenter, single-arm, open-label study. We planned to enroll 55 patients with histopathologically or cytologically confirmed stage IV nsqNSCLC with brain metastases and negative driver gene reports within three months. The aim of this study is to evaluate the safety, tolerability and efficacy of ivoricizumab combined with chemotherapy as the first-line treatment for patients with brain metastases from NSQ non-small cell lung cancer (NSCLC) without driver genes. Eligible subjects were selected and entered the study in sequence. The trial was divided into combination chemotherapy period (C1-C4/C6) and maintenance treatment period (C5/C7-C32). During the combined chemotherapy period, all subjects were treated with everciximab injection and chemotherapy drugs after entering the study, and during the maintenance treatment period, they were treated with everciximab injection and pemetrexed. Every 3 weeks (Q3W) was a treatment cycle. The efficacy was evaluated every 2 cycles in the combined chemotherapy period and every 3 cycles in the maintenance treatment period. All the participants received treatment until they withdrew consent, had disease progression, had unacceptable toxicity, had to discontinue the drug as judged by the investigator, were lost to follow-up, died, or had received ivorximab for 2 years, whichever occurred first. After the end of treatment, the patients were followed up until death. If there are abnormal items, for the safety of subjects, researchers can judge whether to add unplanned follow-up according to the actual situation.
Investigators
Li-kun Chen
senior doctor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •The subjects voluntarily participated in the clinical study and had not received any systemic anti-tumor treatment (including any chemotherapy, targeted therapy, immunotherapy, etc.)
- •Male or female subjects aged 18-75 years (including the cutoff) at the time of signing the ICF
- •patients with histopathologically or cytologically confirmed stage IV non-squamous non-small cell lung cancer (nsqNSCLC) with brain metastases
- •Patients were required to provide a genetic testing report that showed negative driver genes, i.e., no EFGR sensitive gene mutation, no ALK or ROS1 gene fusion, no BRAF V600E sensitive gene mutation, and no RET gene fusion
- •If not, qualified tumor tissue or blood should be provided for genetic testing. 5) MRI confirmed brain parenchymal metastasis, with ≥3 brain lesions
- •6: Or patients with 1-2 brain lesions who are not suitable for local treatment or refuse local treatment. At least one measurable brain lesion had to be at least 5mm in diameter. 6) For asymptomatic brain metastases or those with controlled intracranial hypertension after treatment with dehydration, medication could be continued at enrollment or during the study to maintain symptom stability
- •At least one measurable target lesion as assessed by investigator according to RECIST v1.1 within 4 weeks before the first dose
- •ECOG PS score of 0-1
- •predicted survival time ≥12 weeks
- •good vital organ function
Exclusion Criteria
- •known history of severe allergy to any monoclonal antibody (NCI-CTCAE 5.0 \> 3) Or known hypersensitivity to carboplatin/pemetrexed components
- •2: any active infection requiring systemic anti-infective therapy within 14 days before the first dose
- •myocardial infarction with uncontrolled arrhythmia (including QTc interval ≥450 ms in men and ≥470 ms in women) within 6 months before the first dose (QTc interval was calculated with Fridericia's formula)
- •4: Or grade III-IV cardiac dysfunction according to the New York Heart Association (NYHA) standard or left ventricular ejection fraction \<50% by echocardiography
- •subjects with ≥ grade 2 CTCAE peripheral neuropathy
- •subjects had uncontrolled or symptomatic hypercalcemia (\>1.5 mmol/L ionized calcium or calcium \>12 mg/dL or corrected serum calcium \>ULN)
- •subjects with previous or screening history of interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or severely impaired pulmonary function, which may interfere with the detection and treatment of suspected drug-related pulmonary toxicity according to the investigator's judgment
- •untreated active hepatitis B subjects (HBsag-positive and HBV-DNA \> 1000 copies /mL (200 IU/mL) or higher than the lower limit of detection, whichever is higher) and, for those with hepatitis B, required to receive anti-HBV treatment for the duration of the study treatment
- •9: Active hepatitis C subjects (positive for HCV antibodies and HCV-RNA levels above the lower limit of detection)
- •10: Or patients with known active syphilis infection (excluding patients with positive heterologous antibody test, negative non-heterologous antibody test and inactive infection confirmed by clinical judgment)
Arms & Interventions
AK112 combined with chemotherapy
AK112 combined with chemotherapy
Intervention: AK112 Injection
Outcomes
Primary Outcomes
iPFS
Time Frame: iPFS was defined as the time from the date of initiation of firstline setting to the date of intracranial progression or death and was censored at the date of the last tumor assessment (when carried out)
iPFS was defined as the time from the date of initiation of firstline setting to the date of intracranial progression or death and was censored at the date of the last tumor assessment (when carried out)